{"entity":{"id":"treat-ctdna","kind":"trial","name":"TREAT ctDNA","aka":["EORTC-2129-BCG"],"tldr":"A European trial that gives the tablet elacestrant to women whose blood shows hormone-receptor-positive breast cancer returning before scans do, to see whether it delays spread.","summary":"TREAT ctDNA (NCT05512364, EORTC) screens patients with ER-positive, HER2-negative breast cancer for ctDNA every six months; those who become ctDNA-positive by the Signatera assay (or another assay approved for diagnosis) without distant metastasis are randomised 1:1 to elacestrant or their current endocrine therapy (tamoxifen, letrozole, anastrozole or exemestane in the registry). Natera and the Menarini Group are collaborators. The primary endpoint is distant metastasis-free survival; primary completion is estimated for November 2032.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT05512364","url":"https://clinicaltrials.gov/study/NCT05512364"}],"tags":[],"related":["trak-er"],"cancers":["breast-hr-positive"],"sections":[],"technologies":["mrd-testing"],"targets":["estrogen-receptor"],"drugs":["elacestrant","signatera","tamoxifen","letrozole","anastrozole","exemestane"],"companies":["natera"],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05512364","phase":"3","setting":"ER-positive, HER2-negative stage IIB to III breast cancer with ctDNA relapse and no distant metastasis: elacestrant versus continuing the same endocrine therapy","sponsor":"European Organisation for Research and Treatment of Cancer (EORTC)","started":"2023-12-15","startedType":"actual","enrolled":220,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/treat-ctdna/","neighbours":{"trial":[{"id":"trak-er","kind":"trial","name":"TRAK-ER","route":"/trials/trak-er/"}],"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"}],"drug":[{"id":"anastrozole","kind":"drug","name":"Anastrozole","route":"/drugs/anastrozole/"},{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/"},{"id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/"},{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/"},{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/"},{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/"}],"company":[{"id":"natera","kind":"company","name":"Natera","route":"/companies/natera/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}]}}